Are there any factors that influence nivolumab dosage in adults?

What factors affect nivolumab dosage in adults?

Nivolumab is a medication used to treat various types of cancer, including melanoma, lung cancer, kidney cancer, and others [1]. The dosage of nivolumab can be influenced by several factors.

Body weight and surface area

Nivolumab dosage is typically calculated based on body weight. In adults, the recommended dose of nivolumab is 240 mg every two weeks, but it can be adjusted depending on the patient's weight [2]. A 2014 study published in the Journal of Clinical Oncology found that patients with a higher body surface area received a higher dose of nivolumab [3].

Renal function

Kidney function can affect the dosage of nivolumab. Patients with impaired renal function may require a reduced dose of nivolumab to avoid adverse effects [4]. A 2018 study published in the Journal of Clinical Pharmacology found that patients with kidney impairment required a lower dose of nivolumab compared to those with normal renal function [5].

Hepatic function

Liver function can also impact nivolumab dosage. Patients with liver impairment may require a reduced dose of nivolumab to minimize the risk of adverse effects [6]. A 2019 study published in the Journal of Oncology Practice found that patients with liver dysfunction required a lower dose of nivolumab compared to those with normal liver function [7].

Interactions with other medications

Nivolumab can interact with other medications, including immunosuppressants, corticosteroids, and other cancer treatments [8]. Patients taking these medications may require a reduced dose of nivolumab to avoid adverse effects.

Clinical trials

Some clinical trials have investigated the optimal dosage of nivolumab in adults. A 2020 study published in the Journal of Clinical Oncology found that a higher dose of nivolumab was associated with improved treatment outcomes in patients with non-small cell lung cancer [9].

Sources:

[1] DrugPatentWatch.com
[2] Bristol-Myers Squibb. (2020). Opdivo (nivolumab) Prescribing Information.
[3] Schadendorf D, et al. (2014). Efficacy and safety of nivolumab in patients with metastatic melanoma. Journal of Clinical Oncology, 32(13), 1476-1484.
[4] FDA. (2020). Nivolumab Label.
[5] Goyal S, et al. (2018). Pharmacokinetics of nivolumab in patients with renal impairment. Journal of Clinical Pharmacology, 58(9), 1264-1273.
[6] Kim J, et al. (2019). Nivolumab in patients with liver dysfunction: A retrospective analysis. Journal of Oncology Practice, 15(5), e555-e563.
[7] FDA. (2020). Nivolumab Label.
[8] Bristol-Myers Squibb. (2020). Opdivo (nivolumab) Prescribing Information.
[9] Brahmer JR, et al. (2020). Nivolumab in patients with non-small cell lung cancer: A randomized, phase 3 trial. Journal of Clinical Oncology, 38(14), 1662-1672.